Dr. Abbey Doses First Patient in Phase III LUGANO Clinical Trial of Duravyu for Wet AMD
Texas Retina Associates Director of Clinical Research for Dallas Ashkan Abbey, MD, recently dosed the first patient in the Phase III LUGANO clinical trial of Duravyu (formerly EYP-1901) for the treatment of
read more
Phone Issues Have Been Resolved
Our phones should be working properly again. The issues we experienced on Friday, January 5th, been resolved. We apologize again for any inconvenience this may have caused.
read more
National Doctor’s Day
Today we celebrate and thank all 17 of our physicians at Texas Retina Associates as well as all of the physicians who serve our communities. “The good physician treats the disease; the
read more
Dr. Wang Published Article on Long-term Inflammation Control and Uveitis in Retina Today
Texas Retina Associates’ Robert C. Wang, MD, shared three case studies in an article titled “Long-term Inflammation Control Benefits All Types of Uveitis” published in the November/December 2020 issue of the medical
read more